FY2025 EPS Estimates for Intra-Cellular Therapies, Inc. Lifted by Analyst (NASDAQ:ITCI)

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) – Equities researchers at Leerink Partnrs increased their FY2025 EPS estimates for Intra-Cellular Therapies in a report issued on Tuesday, May 7th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceutical company will earn $1.50 per share for the year, up from their prior estimate of $1.35. The consensus estimate for Intra-Cellular Therapies’ current full-year earnings is ($0.59) per share. Leerink Partnrs also issued estimates for Intra-Cellular Therapies’ FY2026 earnings at $3.15 EPS and FY2028 earnings at $6.80 EPS.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.15. The business had revenue of $144.90 million during the quarter, compared to analysts’ expectations of $141.41 million. Intra-Cellular Therapies had a negative return on equity of 23.02% and a negative net margin of 30.08%. The firm’s quarterly revenue was up 52.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.46) EPS.

Several other analysts also recently issued reports on ITCI. Needham & Company LLC reiterated a “buy” rating and set a $90.00 price target on shares of Intra-Cellular Therapies in a research note on Tuesday. Bank of America increased their price target on Intra-Cellular Therapies from $82.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Canaccord Genuity Group boosted their price objective on shares of Intra-Cellular Therapies from $100.00 to $107.00 and gave the stock a “buy” rating in a research note on Tuesday, April 23rd. Robert W. Baird raised their target price on shares of Intra-Cellular Therapies from $83.00 to $103.00 and gave the company an “outperform” rating in a research note on Wednesday, April 17th. Finally, The Goldman Sachs Group boosted their target price on shares of Intra-Cellular Therapies from $67.00 to $77.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 17th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Intra-Cellular Therapies currently has an average rating of “Moderate Buy” and a consensus price target of $90.17.

Intra-Cellular Therapies Trading Down 5.9 %

ITCI stock opened at $67.00 on Thursday. The firm has a market cap of $6.49 billion, a PE ratio of -45.89 and a beta of 1.01. Intra-Cellular Therapies has a 1 year low of $45.50 and a 1 year high of $84.89. The company has a fifty day simple moving average of $69.03 and a 200 day simple moving average of $65.86.

Insider Buying and Selling at Intra-Cellular Therapies

In related news, CEO Sharon Mates sold 40,712 shares of the business’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $66.50, for a total value of $2,707,348.00. Following the sale, the chief executive officer now owns 1,050,309 shares of the company’s stock, valued at approximately $69,845,548.50. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, EVP Michael Halstead sold 7,907 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $69.53, for a total transaction of $549,773.71. Following the transaction, the executive vice president now directly owns 29,700 shares in the company, valued at $2,065,041. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Sharon Mates sold 40,712 shares of the company’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $66.50, for a total value of $2,707,348.00. Following the transaction, the chief executive officer now directly owns 1,050,309 shares in the company, valued at approximately $69,845,548.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 168,487 shares of company stock valued at $11,364,950. 3.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Intra-Cellular Therapies

Several large investors have recently made changes to their positions in ITCI. Xponance Inc. grew its holdings in Intra-Cellular Therapies by 3.0% during the 4th quarter. Xponance Inc. now owns 5,676 shares of the biopharmaceutical company’s stock worth $407,000 after acquiring an additional 163 shares during the period. Regal Investment Advisors LLC grew its stake in Intra-Cellular Therapies by 1.4% in the third quarter. Regal Investment Advisors LLC now owns 13,610 shares of the biopharmaceutical company’s stock valued at $709,000 after acquiring an additional 186 shares during the period. State Board of Administration of Florida Retirement System increased its holdings in shares of Intra-Cellular Therapies by 0.8% in the third quarter. State Board of Administration of Florida Retirement System now owns 26,796 shares of the biopharmaceutical company’s stock worth $1,396,000 after acquiring an additional 200 shares in the last quarter. Bailard Inc. lifted its holdings in shares of Intra-Cellular Therapies by 1.2% during the 4th quarter. Bailard Inc. now owns 17,080 shares of the biopharmaceutical company’s stock valued at $1,223,000 after purchasing an additional 200 shares in the last quarter. Finally, Parallel Advisors LLC grew its position in shares of Intra-Cellular Therapies by 16.3% in the 4th quarter. Parallel Advisors LLC now owns 1,564 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 219 shares during the period. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.